Preview

Drug development & registration

Advanced search

Federal State Unitary Enterprise "Federal Center of Nuclear Medicine Projects Design and Development" of FMBA of Russia as a Benchmark of the Nuclear Medicine Evolution in Russia

Abstract

Federal State Unitary Enterprise "Federal center of nuclear medicine projects design and development" of FMBA of Russia is the leading Russian manufacturer of therapeutic radiopharmaceutical preparations (RPP) is celebrating its 55th anniversary this year. The Enterprise was at the origin of the development of nuclear medicine in Russia and remains the largest manufacturer of therapeutic RPPs in our country. The account of the company's evolution is the story of the advancement of nuclear medicine in Russia. In the present article, we offer an analysis of the production experience the company accumulated over the years of operation as well as the major achievements and hardships the Enterprise dealt with. We put a special emphasis on the reciprocity of the Enterprise's background and progress with general trends in the development of nuclear medicine in Russia.

About the Authors

S. V. Loseva

Russian Federation

Svetlana V. Loseva



O. N. Ilyushchenko

Russian Federation

Olga N. Ilyushchenko



A. V. Antonyuk

Russian Federation

Alla V. Antonyuk



T. V. Kishkina

Russian Federation

Tamara V. Kishkina



O. A. Nagurnyy

Russian Federation

Oleg A. Nagurnyy



M. A. Zolotarev

Russian Federation

Maxim A. Zolotarev



M. V. Goryacheva

Russian Federation

Maria V. Goryacheva



A. V. Zverev

Russian Federation

Alexandr V. Zverev



Yu. V. Rangaev

Russian Federation

Yuriy V. Rangaev



Supplementary files

1. Графический абстракт
Subject
Type Исследовательские инструменты
View (1MB)    
Indexing metadata ▾

Review

For citations:


Loseva S.V., Ilyushchenko O.N., Antonyuk A.V., Kishkina T.V., Nagurnyy O.A., Zolotarev M.A., Goryacheva M.V., Zverev A.V., Rangaev Yu.V. Federal State Unitary Enterprise "Federal Center of Nuclear Medicine Projects Design and Development" of FMBA of Russia as a Benchmark of the Nuclear Medicine Evolution in Russia. Drug development & registration. 2022;11(2):16-25. (In Russ.)

Views: 1149


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2305-2066 (Print)
ISSN 2658-5049 (Online)